BioSpace News Archive

Innovus Pharma today announced the approval of its Product License Application (“PLA”) in Canada for its lidocaine-based cream Xyralid (DIN 02471434), for the relief of pain and symptoms caused by hemorrhoids.

This agreement brings another innovative technology to Certis USA’s growing platform of biopesticides based on Bacillus technology, such as Bacillus thuringiensis, Bacillus amyloliquefaciens and Bacillus mycoides.

Gamida Cell today announced the initiation of a phase I study evaluating its proprietary NAM-expanded natural killer cells (NAM-NK Cells) in patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (NHL) and multiple myeloma.

Aerie announced the appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance, reporting to Cindy Martin, Aerie’s Vice President of Regulatory, and Tim Swan as Director of Sales and Transparency Operations, reporting to Gerry McKenzie, Aerie’s Vice President of Commercial Operations.

Cellect announced that it has signed an agreement with the Hadassah Medical Center to conduct clinical trials on cancer patients in Cellect’s ongoing Phase I/II study.

RXi Pharma outlined its 2018 business strategy during a webcast presentation at the Biotech Showcase conference which brought together over 3,500 life science decision makers and investors from over 50 countries to collaborate and discuss industry trends.

Ophthotech announced today the election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to its Board of Directors, effective immediately.

The partnership focuses on development, regulatory support and commercialization of companion diagnostics.

With the assistance of Greenhill, MabVax is currently in advanced discussions with a variety of interested parties for potential multiple transaction proposals as well as continuing to identify new opportunities.

The financial results and live webcast will be accessible through the Investor Relations section of the Company’s Web site at http://investors.impaxlabs.com.